BioVie Lawsuit Submission Form

Company: BioVie Inc.

Ticker: (NASDAQ) BIVI

Deadline

Passed

Lead Plaintiff Deadline: March 19, 2024

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

WhatsApp

WhatsApp Channel QR Code

Scan the QR code or click the button to join.

Get Updates by Email

Subscribe for email notifications.

No spam, opt-out anytime, alert list is free.

Allegations

The filed complaint alleges that BioVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) the COVID-19 pandemic significantly and negatively impacted the Company's ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) due to lack of proper oversight and reliance on contract research organizations, the data from defendants' Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie's business, operations, prospects, and compliance with current good clinical practices were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.